Compare ERIC & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ERIC | TEVA |
|---|---|---|
| Founded | 1876 | 1901 |
| Country | Sweden | Israel |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.2B | 30.2B |
| IPO Year | N/A | N/A |
| Metric | ERIC | TEVA |
|---|---|---|
| Price | $11.25 | $33.38 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $10.40 | ★ $37.25 |
| AVG Volume (30 Days) | ★ 9.9M | 9.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.73% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.46 | $2.97 |
| P/E Ratio | ★ $12.13 | $28.19 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.96 | $12.47 |
| 52 Week High | $11.38 | $37.35 |
| Indicator | ERIC | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 69.02 | 50.68 |
| Support Level | $11.08 | $33.70 |
| Resistance Level | $11.38 | $35.32 |
| Average True Range (ATR) | 0.19 | 1.04 |
| MACD | -0.01 | -0.22 |
| Stochastic Oscillator | 100.00 | 4.45 |
Ericsson provides telecom equipment and services that are primarily used to build and operate mobile networks. The firm divides its business into three segments: networks, cloud and software services, and enterprise. Wireless carriers have traditionally been the firm's primary customers, but it is pushing to cater more to enterprises as well, as both try to take advantage of 5G capabilities and utilize "as-a-service" communications platforms. The company also licenses its patents to handset manufacturers.
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.